Global PARP Inhibitors for Breast Cancer Market Growth (Status and Outlook) 2023-2029

March 2023 | 62 pages | ID: G6F59D914DCEN
LP Information

Abstracts

The report requires updating with new data and is sent in 48 hours after order is placed.

LPI (LP Information)' newest research report, the “PARP Inhibitors for Breast Cancer Industry Forecast” looks at past sales and reviews total world PARP Inhibitors for Breast Cancer sales in 2022, providing a comprehensive analysis by region and market sector of projected PARP Inhibitors for Breast Cancer sales for 2023 through 2029. With PARP Inhibitors for Breast Cancer sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world PARP Inhibitors for Breast Cancer industry.

This Insight Report provides a comprehensive analysis of the global PARP Inhibitors for Breast Cancer landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on PARP Inhibitors for Breast Cancer portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global PARP Inhibitors for Breast Cancer market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for PARP Inhibitors for Breast Cancer and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global PARP Inhibitors for Breast Cancer.

The global PARP Inhibitors for Breast Cancer market size is projected to grow from US$ million in 2022 to US$ million in 2029; it is expected to grow at a CAGR of % from 2023 to 2029.

United States market for PARP Inhibitors for Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

China market for PARP Inhibitors for Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Europe market for PARP Inhibitors for Breast Cancer is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.

Global key PARP Inhibitors for Breast Cancer players cover AstraZeneca, Everest Pharmaceuticals and Pfizer, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.

This report presents a comprehensive overview, market shares, and growth opportunities of PARP Inhibitors for Breast Cancer market by product type, application, key players and key regions and countries.

Market Segmentation:

Segmentation by type

• Olaparib
• Talazoparib

Segmentation by application

• Hospital
• Clinic
• Drug Center
• Other

This report also splits the market by region:

• Americas
• United States
• Canada
• Mexico
• Brazil
• APAC
• China
• Japan
• Korea
• Southeast Asia
• India
• Australia
• Europe
• Germany
• France
• UK
• Italy
• Russia
• Middle East & Africa
• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• AstraZeneca
• Everest Pharmaceuticals
• Pfizer

Contents

1 SCOPE OF THE REPORT

1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats

2 EXECUTIVE SUMMARY

2.1 World Market Overview
  2.1.1 Global PARP Inhibitors for Breast Cancer Market Size 2018-2029
  2.1.2 PARP Inhibitors for Breast Cancer Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 PARP Inhibitors for Breast Cancer Segment by Type
  2.2.1 Olaparib
  2.2.2 Talazoparib
2.3 PARP Inhibitors for Breast Cancer Market Size by Type
  2.3.1 PARP Inhibitors for Breast Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029)
  2.3.2 Global PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
2.4 PARP Inhibitors for Breast Cancer Segment by Application
  2.4.1 Hospital
  2.4.2 Clinic
  2.4.3 Drug Center
  2.4.4 Other
2.5 PARP Inhibitors for Breast Cancer Market Size by Application
  2.5.1 PARP Inhibitors for Breast Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029)
  2.5.2 Global PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)

3 PARP INHIBITORS FOR BREAST CANCER MARKET SIZE BY PLAYER

3.1 PARP Inhibitors for Breast Cancer Market Size Market Share by Players
  3.1.1 Global PARP Inhibitors for Breast Cancer Revenue by Players (2018-2023)
  3.1.2 Global PARP Inhibitors for Breast Cancer Revenue Market Share by Players (2018-2023)
3.2 Global PARP Inhibitors for Breast Cancer Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
  3.3.1 Competition Landscape Analysis
  3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion

4 PARP INHIBITORS FOR BREAST CANCER BY REGIONS

4.1 PARP Inhibitors for Breast Cancer Market Size by Regions (2018-2023)
4.2 Americas PARP Inhibitors for Breast Cancer Market Size Growth (2018-2023)
4.3 APAC PARP Inhibitors for Breast Cancer Market Size Growth (2018-2023)
4.4 Europe PARP Inhibitors for Breast Cancer Market Size Growth (2018-2023)
4.5 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Growth (2018-2023)

5 AMERICAS

5.1 Americas PARP Inhibitors for Breast Cancer Market Size by Country (2018-2023)
5.2 Americas PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023)
5.3 Americas PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil

6 APAC

6.1 APAC PARP Inhibitors for Breast Cancer Market Size by Region (2018-2023)
6.2 APAC PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023)
6.3 APAC PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia

7 EUROPE

7.1 Europe PARP Inhibitors for Breast Cancer by Country (2018-2023)
7.2 Europe PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023)
7.3 Europe PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia

8 MIDDLE EAST & AFRICA

8.1 Middle East & Africa PARP Inhibitors for Breast Cancer by Region (2018-2023)
8.2 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023)
8.3 Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries

9 MARKET DRIVERS, CHALLENGES AND TRENDS

9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends

10 GLOBAL PARP INHIBITORS FOR BREAST CANCER MARKET FORECAST

10.1 Global PARP Inhibitors for Breast Cancer Forecast by Regions (2024-2029)
  10.1.1 Global PARP Inhibitors for Breast Cancer Forecast by Regions (2024-2029)
  10.1.2 Americas PARP Inhibitors for Breast Cancer Forecast
  10.1.3 APAC PARP Inhibitors for Breast Cancer Forecast
  10.1.4 Europe PARP Inhibitors for Breast Cancer Forecast
  10.1.5 Middle East & Africa PARP Inhibitors for Breast Cancer Forecast
10.2 Americas PARP Inhibitors for Breast Cancer Forecast by Country (2024-2029)
  10.2.1 United States PARP Inhibitors for Breast Cancer Market Forecast
  10.2.2 Canada PARP Inhibitors for Breast Cancer Market Forecast
  10.2.3 Mexico PARP Inhibitors for Breast Cancer Market Forecast
  10.2.4 Brazil PARP Inhibitors for Breast Cancer Market Forecast
10.3 APAC PARP Inhibitors for Breast Cancer Forecast by Region (2024-2029)
  10.3.1 China PARP Inhibitors for Breast Cancer Market Forecast
  10.3.2 Japan PARP Inhibitors for Breast Cancer Market Forecast
  10.3.3 Korea PARP Inhibitors for Breast Cancer Market Forecast
  10.3.4 Southeast Asia PARP Inhibitors for Breast Cancer Market Forecast
  10.3.5 India PARP Inhibitors for Breast Cancer Market Forecast
  10.3.6 Australia PARP Inhibitors for Breast Cancer Market Forecast
10.4 Europe PARP Inhibitors for Breast Cancer Forecast by Country (2024-2029)
  10.4.1 Germany PARP Inhibitors for Breast Cancer Market Forecast
  10.4.2 France PARP Inhibitors for Breast Cancer Market Forecast
  10.4.3 UK PARP Inhibitors for Breast Cancer Market Forecast
  10.4.4 Italy PARP Inhibitors for Breast Cancer Market Forecast
  10.4.5 Russia PARP Inhibitors for Breast Cancer Market Forecast
10.5 Middle East & Africa PARP Inhibitors for Breast Cancer Forecast by Region (2024-2029)
  10.5.1 Egypt PARP Inhibitors for Breast Cancer Market Forecast
  10.5.2 South Africa PARP Inhibitors for Breast Cancer Market Forecast
  10.5.3 Israel PARP Inhibitors for Breast Cancer Market Forecast
  10.5.4 Turkey PARP Inhibitors for Breast Cancer Market Forecast
  10.5.5 GCC Countries PARP Inhibitors for Breast Cancer Market Forecast
10.6 Global PARP Inhibitors for Breast Cancer Forecast by Type (2024-2029)
10.7 Global PARP Inhibitors for Breast Cancer Forecast by Application (2024-2029)

11 KEY PLAYERS ANALYSIS

11.1 AstraZeneca
  11.1.1 AstraZeneca Company Information
  11.1.2 AstraZeneca PARP Inhibitors for Breast Cancer Product Offered
  11.1.3 AstraZeneca PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
  11.1.4 AstraZeneca Main Business Overview
  11.1.5 AstraZeneca Latest Developments
11.2 Everest Pharmaceuticals
  11.2.1 Everest Pharmaceuticals Company Information
  11.2.2 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product Offered
  11.2.3 Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
  11.2.4 Everest Pharmaceuticals Main Business Overview
  11.2.5 Everest Pharmaceuticals Latest Developments
11.3 Pfizer
  11.3.1 Pfizer Company Information
  11.3.2 Pfizer PARP Inhibitors for Breast Cancer Product Offered
  11.3.3 Pfizer PARP Inhibitors for Breast Cancer Revenue, Gross Margin and Market Share (2018-2023)
  11.3.4 Pfizer Main Business Overview
  11.3.5 Pfizer Latest Developments

12 RESEARCH FINDINGS AND CONCLUSION

List Of Tables

LIST OF TABLES

Table 1. PARP Inhibitors for Breast Cancer Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Olaparib
Table 3. Major Players of Talazoparib
Table 4. PARP Inhibitors for Breast Cancer Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Table 7. PARP Inhibitors for Breast Cancer Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Table 10. Global PARP Inhibitors for Breast Cancer Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Player (2018-2023)
Table 12. PARP Inhibitors for Breast Cancer Key Players Head office and Products Offered
Table 13. PARP Inhibitors for Breast Cancer Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global PARP Inhibitors for Breast Cancer Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global PARP Inhibitors for Breast Cancer Market Size Market Share by Regions (2018-2023)
Table 18. Global PARP Inhibitors for Breast Cancer Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas PARP Inhibitors for Breast Cancer Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas PARP Inhibitors for Breast Cancer Market Size Market Share by Country (2018-2023)
Table 22. Americas PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Table 24. Americas PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Table 26. APAC PARP Inhibitors for Breast Cancer Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC PARP Inhibitors for Breast Cancer Market Size Market Share by Region (2018-2023)
Table 28. APAC PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Table 30. APAC PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Table 32. Europe PARP Inhibitors for Breast Cancer Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe PARP Inhibitors for Breast Cancer Market Size Market Share by Country (2018-2023)
Table 34. Europe PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Table 36. Europe PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of PARP Inhibitors for Breast Cancer
Table 45. Key Market Challenges & Risks of PARP Inhibitors for Breast Cancer
Table 46. Key Industry Trends of PARP Inhibitors for Breast Cancer
Table 47. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global PARP Inhibitors for Breast Cancer Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global PARP Inhibitors for Breast Cancer Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. AstraZeneca Details, Company Type, PARP Inhibitors for Breast Cancer Area Served and Its Competitors
Table 52. AstraZeneca PARP Inhibitors for Breast Cancer Product Offered
Table 53. AstraZeneca PARP Inhibitors for Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. AstraZeneca Main Business
Table 55. AstraZeneca Latest Developments
Table 56. Everest Pharmaceuticals Details, Company Type, PARP Inhibitors for Breast Cancer Area Served and Its Competitors
Table 57. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Product Offered
Table 58. Everest Pharmaceuticals Main Business
Table 59. Everest Pharmaceuticals PARP Inhibitors for Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Everest Pharmaceuticals Latest Developments
Table 61. Pfizer Details, Company Type, PARP Inhibitors for Breast Cancer Area Served and Its Competitors
Table 62. Pfizer PARP Inhibitors for Breast Cancer Product Offered
Table 63. Pfizer Main Business
Table 64. Pfizer PARP Inhibitors for Breast Cancer Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Pfizer Latest Developments

List Of Figures

LIST OF FIGURES

Figure 1. PARP Inhibitors for Breast Cancer Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global PARP Inhibitors for Breast Cancer Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. PARP Inhibitors for Breast Cancer Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. PARP Inhibitors for Breast Cancer Sales Market Share by Country/Region (2022)
Figure 8. PARP Inhibitors for Breast Cancer Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global PARP Inhibitors for Breast Cancer Market Size Market Share by Type in 2022
Figure 10. PARP Inhibitors for Breast Cancer in Hospital
Figure 11. Global PARP Inhibitors for Breast Cancer Market: Hospital (2018-2023) & ($ Millions)
Figure 12. PARP Inhibitors for Breast Cancer in Clinic
Figure 13. Global PARP Inhibitors for Breast Cancer Market: Clinic (2018-2023) & ($ Millions)
Figure 14. PARP Inhibitors for Breast Cancer in Drug Center
Figure 15. Global PARP Inhibitors for Breast Cancer Market: Drug Center (2018-2023) & ($ Millions)
Figure 16. PARP Inhibitors for Breast Cancer in Other
Figure 17. Global PARP Inhibitors for Breast Cancer Market: Other (2018-2023) & ($ Millions)
Figure 18. Global PARP Inhibitors for Breast Cancer Market Size Market Share by Application in 2022
Figure 19. Global PARP Inhibitors for Breast Cancer Revenue Market Share by Player in 2022
Figure 20. Global PARP Inhibitors for Breast Cancer Market Size Market Share by Regions (2018-2023)
Figure 21. Americas PARP Inhibitors for Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 22. APAC PARP Inhibitors for Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 23. Europe PARP Inhibitors for Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 24. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size 2018-2023 ($ Millions)
Figure 25. Americas PARP Inhibitors for Breast Cancer Value Market Share by Country in 2022
Figure 26. United States PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 27. Canada PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 28. Mexico PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 29. Brazil PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 30. APAC PARP Inhibitors for Breast Cancer Market Size Market Share by Region in 2022
Figure 31. APAC PARP Inhibitors for Breast Cancer Market Size Market Share by Type in 2022
Figure 32. APAC PARP Inhibitors for Breast Cancer Market Size Market Share by Application in 2022
Figure 33. China PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 34. Japan PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 35. Korea PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 36. Southeast Asia PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 37. India PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 38. Australia PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 39. Europe PARP Inhibitors for Breast Cancer Market Size Market Share by Country in 2022
Figure 40. Europe PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Figure 41. Europe PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Figure 42. Germany PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 43. France PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 44. UK PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 45. Italy PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 46. Russia PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 47. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Market Share by Region (2018-2023)
Figure 48. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Market Share by Type (2018-2023)
Figure 49. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size Market Share by Application (2018-2023)
Figure 50. Egypt PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 51. South Africa PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 52. Israel PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 53. Turkey PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 54. GCC Country PARP Inhibitors for Breast Cancer Market Size Growth 2018-2023 ($ Millions)
Figure 55. Americas PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 56. APAC PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 57. Europe PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 58. Middle East & Africa PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 59. United States PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 60. Canada PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 61. Mexico PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 62. Brazil PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 63. China PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 64. Japan PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 65. Korea PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 66. Southeast Asia PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 67. India PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 68. Australia PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 69. Germany PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 70. France PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 71. UK PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 72. Italy PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 73. Russia PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 74. Spain PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 75. Egypt PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 76. South Africa PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 77. Israel PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 78. Turkey PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 79. GCC Countries PARP Inhibitors for Breast Cancer Market Size 2024-2029 ($ Millions)
Figure 80. Global PARP Inhibitors for Breast Cancer Market Size Market Share Forecast by Type (2024-2029)
Figure 81. Global PARP Inhibitors for Breast Cancer Market Size Market Share Forecast by Application (2024-2029)